In order to gather both qualitative and quantitative insights, supply-side and demand-side stakeholders were interviewed during the primary research process. CEOs, Chief Technical Officers, Heads of Cell & Gene Therapy Manufacturing, Quality Assurance Directors, and Business Development Heads from ATMP-focused CDMOs, viral vector producers, and plasmid DNA providers were among the supply-side sources. Chief Scientific Officers, VPs of Technical Operations, Head of External Manufacturing, and procurement leads from biotechnology and pharmaceutical businesses creating tissue-engineered products, gene treatments, and cell therapies were examples of demand-side sources.
Primary research verified capacity expansion schedules and facility build-outs; validated market segmentation across vector manufacturing (lentiviral, AAV, retroviral), cell therapy processing (autologous, allogeneic), and analytical testing services; and acquired information on regulatory compliance tactics, pricing models for GMP manufacturing slots, and partnership structures between innovators and CDMOs.
Primary Respondent Breakdown:
By Designation: C-level Primaries (32%), Director Level (31%), Others (37%)
By Region: North America (38%), Europe (30%), Asia-Pacific (25%), Rest of World (7%)
Manufacturing capacity analysis and service revenue mapping were used to determine the global market valuation. The methodology comprised:
Finding more than fifty important CDMOs in emerging markets, North America, Europe, and Asia-Pacific
Service mapping for the creation of plasmid DNA, cell treatment (CAR-T, stem cells, iPSCs), fill-finish services, and viral vectors (AAV, lentiviral, retroviral).
Analysis of annual revenues for ATMP manufacturing portfolios, both reported and modeled
Coverage of CDMOs accounting for 75–80% of the world's ATMP production capacity in 2024
Extrapolation of segment-specific valuations for gene therapy CDMO, cell therapy CDMO, and viral vector manufacturing markets using top-down (CDMO revenue validation against reported client pipelines) and bottom-up (number of clinical/commercial programs × average contract value by phase) approaches
